The FDA has issued a Complete Response Letter to Scholar Rock regarding the BLA for apitegromab for the treatment of spinal muscular atrophy.

The risk for dementia was significantly higher in those with prefrailty and frailty compared with nonfrail individuals.

HealthDay News — Higher repetitive head impact (RHI) exposure is associated with microstructural disruption at the depths of sulci, according to a study published online Sept. 17 in Neurology.

Topline data were announced from a pivotal study evaluating zilganersen in children and adults living with Alexander disease.

Epilepsy patients with vs without psychiatric comorbidities have a higher proportion of abnormal brain MRI and EEG findings.

Racial and ethnic disparities in United States stroke care vary by intervention type at the national and state levels.

Psychological therapies are effective for people with multiple sclerosis, showing benefits across mental health, cognitive function, physical well-being, and quality of life.

The maker of Tylenol is pushing back against resurfaced claims that its popular pain reliever is unsafe for pregnant women.

Ocrelizumab is noninferior to fingolimod, demonstrating efficacy and safety in children and adolescents with ...

The FDA has extended the review period of the New Drug Application for tolebrutinib for the treatment of non-relapsing, secondary progressive MS and to slow disability accumulation independent of ...

Leber hereditary optic neuropathy (LHON) is a genetic mitochondrial disorder that damages retinal ganglion cells, resulting in rapid vision loss. Idebenone is expected to restore mitochondrial ...

A decades-old cancer drug may soon be approved to help kids with certain autism-related symptoms linked to folate deficiency.